NO20003372L - Erytropoietinderivater - Google Patents

Erytropoietinderivater

Info

Publication number: NO20003372L
Authority: NO; Norway
Prior art keywords: erythropoietin derivatives; erythropoietin; derivatives
Prior art date: 1999-07-02

Application number

NO20003372A

Other languages

English (en)

Other versions

NO327043B1 (no

NO20003372D0 (no

Inventor

Pascal Sebastian Bailon

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-02

Filing date

2000-06-28

Publication date

2001-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003372(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2000-06-28 Publication of NO20003372D0 publication Critical patent/NO20003372D0/no

2001-01-03 Publication of NO20003372L publication Critical patent/NO20003372L/no

2009-04-06 Publication of NO327043B1 publication Critical patent/NO327043B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Virology (AREA)
Psychiatry (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20003372A 1999-07-02 2000-06-28 Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling. NO327043B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US14225499P	1999-07-02	1999-07-02
US15022599P	1999-08-23	1999-08-23
US15154899P	1999-08-31	1999-08-31
US16615199P	1999-11-17	1999-11-17

Publications (3)

Publication Number	Publication Date
NO20003372D0 NO20003372D0 (no)	2000-06-28
NO20003372L true NO20003372L (no)	2001-01-03
NO327043B1 NO327043B1 (no)	2009-04-06

Family

ID=27495518

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003372A NO327043B1 (no)	1999-07-02	2000-06-28	Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling.
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Country Status (51)

Country	Link
US (2)	US6583272B1 (no)
EP (2)	EP1839676A3 (no)
JP (2)	JP3727009B2 (no)
KR (1)	KR100593143B1 (no)
CN (2)	CN1184233C (no)
AR (2)	AR024625A1 (no)
AT (1)	ATE370748T1 (no)
AU (1)	AU736067B2 (no)
BG (1)	BG65449B1 (no)
BR (2)	BR0002276A (no)
CA (1)	CA2310536C (no)
CO (1)	CO5190661A1 (no)
CY (2)	CY1107719T1 (no)
CZ (1)	CZ299516B6 (no)
DE (3)	DE122007000064I2 (no)
DK (1)	DK1064951T3 (no)
DO (1)	DOP2000000030A (no)
EA (1)	EA003777B1 (no)
ES (2)	ES2289985T3 (no)
FR (2)	FR2795734B1 (no)
GB (2)	GB2353281B (no)
GC (1)	GC0000197A (no)
GE (1)	GEP20022804B (no)
GT (1)	GT200000109A (no)
HR (1)	HRP20000436B1 (no)
HU (1)	HU226233B1 (no)
ID (1)	ID26447A (no)
IL (1)	IL137056A0 (no)
IS (1)	IS2492B (no)
IT (1)	IT1318606B1 (no)
LU (1)	LU91363I2 (no)
MA (1)	MA26746A1 (no)
MX (1)	MXPA00006547A (no)
MY (1)	MY128500A (no)
NL (1)	NL300289I9 (no)
NO (2)	NO327043B1 (no)
NZ (1)	NZ505454A (no)
OA (1)	OA11442A (no)
PA (1)	PA8497801A1 (no)
PE (1)	PE20010297A1 (no)
PL (1)	PL202758B1 (no)
PT (1)	PT1064951E (no)
RS (1)	RS49928B (no)
SG (1)	SG92717A1 (no)
SI (1)	SI1064951T1 (no)
SK (1)	SK286301B6 (no)
SV (1)	SV2002000120A (no)
TN (1)	TNSN00147A1 (no)
TR (1)	TR200001956A2 (no)
TW (1)	TWI235667B (no)
UY (1)	UY26228A1 (no)

Families Citing this family (230)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69824039T2 (de)	1997-12-08	2005-08-18	Lexigen Pharmaceuticals Corp., Lexington	Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) *	1998-02-25	2003-06-05	Stephen Gillies	Enhancing the circulating half life of antibody-based fusion proteins
JP2002511432A (ja) *	1998-04-15	2002-04-16	レキシジェンファーマシューティカルズコーポレイション	新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
US7304150B1 (en) *	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) *	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
PL202058B1 (pl) *	1999-08-09	2009-05-29	Merck Patent Gmbh	Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
AU2154401A (en)	1999-11-12	2001-05-30	Merck Patent Gmbh	Erythropoietin forms with improved properties
US20050202538A1 (en) *	1999-11-12	2005-09-15	Merck Patent Gmbh	Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001058957A2 (en)	2000-02-11	2001-08-16	Lexigen Pharmaceuticals Corp.	Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1311285E (pt) *	2000-05-15	2005-06-30	Hoffmann La Roche	Composicao farmaceutica liquida contendo um derivado de eritropoietina
CA2412845C (en) *	2000-06-29	2014-07-22	Lexigen Pharmaceuticals Corp.	Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU2001290312A1 (en) *	2000-10-16	2002-04-29	Chugai Seiyaku Kabushiki Kaisha	Peg-modified erythropoietin
EP1345628B1 (en) *	2000-12-20	2011-04-13	F. Hoffmann-La Roche AG	Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
ES2361824T3 (es) *	2000-12-20	2011-06-22	F. Hoffmann-La Roche Ag	Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1234583A1 (en) *	2001-02-23	2002-08-28	F. Hoffmann-La Roche Ag	PEG-conjugates of HGF-NK4
BR0207854A (pt) *	2001-03-07	2004-08-24	Merck Patent Gmbh	Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
US6992174B2 (en) *	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
EP1383785B1 (en)	2001-05-03	2011-03-16	Merck Patent GmbH	Recombinant tumor specific antibody and use thereof
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
KR100467751B1 (ko)	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN100390282C (zh) *	2001-12-04	2008-05-28	默克专利有限公司	具有调节的选择性的il-2融合蛋白
DK1463823T3 (da) *	2001-12-06	2013-06-03	Fibrogen Inc	Fremgangsmåder til forhøjelse af endogent erythropoetin (epo)
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
WO2003078959A2 (en)	2002-03-11	2003-09-25	Ortho Mcneil Pharmaceutical, Inc	Methods for shp1 mediated neuroprotection
CA2491567A1 (en) *	2002-07-01	2004-01-08	The Kenneth S. Warren Institute, Inc.	Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
RU2318004C2 (ru)	2002-07-24	2008-02-27	Ф.Хоффманн-Ля Рош Аг	Добавки в виде полиалкиленгликолевой кислоты
US7459435B2 (en) *	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US20050176627A1 (en) *	2002-09-09	2005-08-11	Anthony Cerami	Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2004022593A2 (en) *	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
MXPA05002591A (es)	2002-09-11	2005-09-20	Fresenius Kabi Gmbh	Derivados de almidon de hidroxialquilo.
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
DE60333121D1 (de) *	2002-12-17	2010-08-05	Merck Patent Gmbh	Pers 14.18, der gd2 bindet und seine fusion mit il-2
US7553930B2 (en)	2003-01-06	2009-06-30	Xencor, Inc.	BAFF variants and methods thereof
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en)	2003-03-31	2009-10-27	Xencor, Inc.	Methods for rational pegylation of proteins
CA2520875A1 (en)	2003-03-31	2004-10-21	Xencor, Inc.	Methods for rational pegylation of proteins
US7642340B2 (en)	2003-03-31	2010-01-05	Xencor, Inc.	PEGylated TNF-α variant proteins
US7279174B2 (en) *	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
PL1625156T3 (pl) *	2003-05-12	2013-03-29	Affymax Inc	Peptydy wiążące się do receptora erytropoetyny
UA88146C2 (ru)	2003-05-12	2009-09-25	Афимакс, Инк.	Новые пептиды, которые связываются с рецептором эритропоэтина
WO2004101600A2 (en) *	2003-05-12	2004-11-25	Affymax, Inc.	Novel poly(ethylene glycol) modified compounds and uses thereof
NZ543934A (en)	2003-05-12	2008-06-30	Affymax Inc	Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
JP2007537986A (ja) *	2003-05-30	2007-12-27	セントカー・インコーポレーテツド	トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
US7662607B2 (en) *	2003-07-30	2010-02-16	New Century Pharmaceuticals, Inc.	Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
WO2005032467A2 (en) *	2003-09-29	2005-04-14	Warren Pharmaceuticals, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
EP1675871A2 (en)	2003-10-10	2006-07-05	Xencor Inc.	Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
ES2460671T3 (es) *	2003-12-19	2014-05-14	F. Hoffmann-La Roche Ag	Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
EP1548031A1 (en) *	2003-12-22	2005-06-29	Dubai Genetics FZ-LLC	Nature-identical erythropoietin
CA2551916C (en) *	2003-12-31	2014-04-29	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005070973A2 (en) *	2004-01-21	2005-08-04	Nektar Therapeutics Al, Corporation	Method of preparing propionic acid-terminated polymers
ZA200606225B (en) *	2004-02-02	2007-11-28	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
JP5191729B2 (ja)	2004-03-11	2013-05-08	フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
US7253650B2 (en)	2004-05-25	2007-08-07	International Business Machines Corporation	Increase productivity at wafer test using probe retest data analysis
WO2009100255A2 (en)	2008-02-08	2009-08-13	Ambrx, Inc.	Modified leptin polypeptides and their uses
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
AU2005310189A1 (en) *	2004-11-11	2006-06-08	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
KR101608083B1 (ko)	2005-01-25	2016-04-01	씨티아이 바이오파마 코포레이션	생체내 반감기가 변경된, 생물학적 활성을 갖는 단백질의접합체
US7714114B2 (en) *	2005-02-16	2010-05-11	Nektar Therapeutics	Conjugates of an EPO moiety and a polymer
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
WO2007041713A1 (en) *	2005-10-04	2007-04-12	Zymogenetics, Inc.	Production and purification of il-29
US8741260B2 (en) *	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) *	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) *	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US20080171696A1 (en) *	2005-10-21	2008-07-17	Avigenics, Inc.	Pharmacodynamically enhanced therapeutic proteins
JP2009514814A (ja) *	2005-10-21	2009-04-09	シナジェバ・バイオファーマ・コーポレイション	グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) *	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
LT1988910T (lt) *	2006-02-28	2018-01-10	Kodiak Sciences Inc.	Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas
WO2007108505A1 (ja)	2006-03-22	2007-09-27	Chugai Seiyaku Kabushiki Kaisha	エリスロポエチン溶液製剤
KR101304081B1 (ko) *	2006-08-04	2013-09-05	프로롱 파마슈티컬스, 엘엘씨	수식된 에리스로포이에틴
EP2051734B1 (en)	2006-08-18	2016-10-05	Armagen Technologies, Inc.	Agents for blood-brain barrier delivery
WO2008065372A2 (en)	2006-11-28	2008-06-05	Nautilus Biotech, S.A.	Modified erythropoietin polypeptides and uses thereof for treatment
EP2111412A2 (en) *	2007-02-02	2009-10-28	Amgen, Inc	Hepcidin and hepcidin antibodies
US20090011040A1 (en) *	2007-05-02	2009-01-08	Naash Muna I	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CL2008002054A1 (es) *	2007-07-17	2009-05-29	Hoffmann La Roche	Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) *	2007-07-17	2009-05-22	Hoffmann La Roche	Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AU2008282496B2 (en) *	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
CA2701032C (en)	2007-09-27	2021-01-26	Amgen Inc.	Pharmaceutical formulations
EP3381445B1 (en)	2007-11-15	2023-10-25	Amgen Inc.	Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US8101706B2 (en) *	2008-01-11	2012-01-24	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8110651B2 (en)	2008-01-11	2012-02-07	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5701064B2 (ja)	2008-01-25	2015-04-15	アムジエン・インコーポレーテツド	フェロポーチン抗体およびその使用方法
TWI395593B (zh)	2008-03-06	2013-05-11	Halozyme Inc	可活化的基質降解酵素之活體內暫時性控制
CA2721229C (en)	2008-04-14	2022-08-23	Halozyme, Inc.	Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2009139822A1 (en)	2008-05-01	2009-11-19	Amgen Inc.	Anti-hepcidin antibodies and methods of use
EP4074327A1 (en)	2008-06-27	2022-10-19	Duke University	Therapeutic agents comprising elastin-like peptides
NZ592250A (en)	2008-09-26	2012-11-30	Lilly Co Eli	Modified animal erythropoietin polypeptides and their uses
CA3019967A1 (en)	2008-11-13	2010-05-20	The General Hospital Corporation	Methods and compositions for regulating iron homeostasis by modulation of bmp-6
KR101493644B1 (ko)	2008-12-09	2015-02-13	할로자임, 아이엔씨	연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
US9533055B2 (en)	2009-03-18	2017-01-03	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
WO2011012296A1 (en)	2009-07-30	2011-02-03	F. Hoffmann-La Roche Ag	Moveable chromatography column separator
WO2011024025A1 (en) *	2009-08-28	2011-03-03	Avesthagen Limited	An erythropoietin analogue and a method thereof
WO2011034604A2 (en)	2009-09-17	2011-03-24	Baxter Healthcare, S.A.	Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US20120264688A1 (en) *	2009-09-23	2012-10-18	Walter Hinderer	Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
PT2485761T (pt)	2009-10-09	2019-05-30	Armagen Inc	Métodos e composições para aumentar a atividade da iduronato 2-sulfatase no snc
EP2490957B1 (en)	2009-10-23	2016-11-23	Amgen, Inc	Vial adapter and system
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
CA2792965A1 (en) *	2010-04-27	2011-11-03	Scil Technology Gmbh	Stable aqueous mia/cd-rap formulations
RS54291B2 (sr)	2010-06-07	2023-12-29	Amgen Inc	Uređaj za isporuku lekova
KR101809878B1 (ko)	2010-07-20	2017-12-15	할로자임, 아이엔씨	항-히알루로난제 투여와 관련된 유해 부작용의 치료
RU2566267C2 (ru)	2010-09-14	2015-10-20	Ф. Хоффманн-Ля Рош Аг	Способ очистки пегилированного эритропоэтина
MX347297B (es)	2011-02-02	2017-04-21	Hoffmann La Roche	Soporte para columna de cromatografía.
WO2012109387A1 (en)	2011-02-08	2012-08-16	Halozyme, Inc.	Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US9480624B2 (en)	2011-03-31	2016-11-01	Amgen Inc.	Vial adapter and system
CA3021845C (en)	2011-04-20	2022-03-29	Amgen Inc.	Autoinjector apparatus
US9993529B2 (en)	2011-06-17	2018-06-12	Halozyme, Inc.	Stable formulations of a hyaluronan-degrading enzyme
IL308846B2 (en)	2011-10-14	2025-03-01	Amgen Inc	Injector and assembly method
WO2013063155A2 (en)	2011-10-24	2013-05-02	Halozyme, Inc.	Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
ES2983576T3 (es)	2011-12-02	2024-10-23	Armagen Inc	Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
EP3130347B1 (en)	2011-12-30	2019-09-18	Halozyme, Inc.	Ph20 polypeptide variants, formulations and uses thereof
KR101809858B1 (ko)	2012-04-04	2017-12-15	할로자임, 아이엔씨	항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
CN102816227A (zh) *	2012-08-30	2012-12-12	深圳赛保尔生物药业有限公司	回收促红细胞生成素的方法
WO2014062856A1 (en)	2012-10-16	2014-04-24	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP3081249B1 (en)	2012-11-21	2020-12-30	Amgen Inc.	Drug delivery device
TWI580451B (zh)	2013-03-15	2017-05-01	安美基公司	用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
AU2014236677B2 (en)	2013-03-15	2018-07-05	Intrinsic Lifesciences Llc	Anti-hepcidin antibodies and uses thereof
TWI592183B (zh)	2013-03-15	2017-07-21	安美基公司	本體輪廓可調適之自動注射器裝置
TWI639449B (zh)	2013-03-15	2018-11-01	美商安美基公司	用於注射器之匣盒
KR102287687B1 (ko)	2013-03-22	2021-08-06	암젠 인크	인젝터 및 조립 방법
TW201534726A (zh)	2013-07-03	2015-09-16	Halozyme Inc	熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015035342A2 (en)	2013-09-08	2015-03-12	Oligasis Llc	Factor viii zwitterionic polymer conjugates
US10758683B2 (en)	2013-10-24	2020-09-01	Amgen Inc.	Drug delivery system with temperature-sensitive control
EP3789064B1 (en)	2013-10-24	2024-11-27	Amgen Inc.	Injector and method of assembly
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
CA2945026C (en)	2014-05-07	2023-10-10	Amgen Inc.	Autoinjector with shock reducing elements
EP4362039A3 (en)	2014-06-03	2024-08-07	Amgen Inc.	Controllable drug delivery system and method of use
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
ES2727137T3 (es)	2014-08-28	2019-10-14	Halozyme Inc	Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
NZ730186A (en)	2014-09-22	2020-04-24	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
MX2021014323A (es)	2014-10-14	2023-02-02	Amgen Inc	Dispositivo de inyección de fármaco con indicadores visuales y audibles.
DK3207130T3 (da)	2014-10-14	2019-11-11	Halozyme Inc	Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
JP6849590B2 (ja)	2014-10-17	2021-03-24	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
ES2898469T3 (es)	2014-12-19	2022-03-07	Amgen Inc	Dispositivo de administración de medicamentos con sensor de proximidad
ES2785311T3 (es)	2014-12-19	2020-10-06	Amgen Inc	Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2976935C (en)	2015-02-17	2020-03-10	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en)	2015-02-27	2022-04-13	Amgen, Inc	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
JP7088454B2 (ja)	2015-12-30	2022-06-21	コディアックサイエンシーズインコーポレイテッド	抗体および抗体複合体
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
EP4035711B1 (en)	2016-03-15	2025-06-04	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
CN105820232B (zh) *	2016-04-08	2019-05-17	昂德生物药业有限公司	单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es)	2016-05-13	2024-02-28	Amgen Inc	Conjunto de cubierta protectora de vial
WO2017200989A1 (en)	2016-05-16	2017-11-23	Amgen Inc.	Data encryption in medical devices with limited computational capability
EP3465124A1 (en)	2016-06-03	2019-04-10	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en)	2016-07-01	2022-03-29	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
PL3484911T3 (pl)	2016-07-15	2021-03-08	F. Hoffmann-La Roche Ag	Sposób oczyszczania PEGylowanej erytropoetyny
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
EP3532127A1 (en)	2016-10-25	2019-09-04	Amgen Inc.	On-body injector
US20190358411A1 (en)	2017-01-17	2019-11-28	Amgen Inc.	Injection devices and related methods of use and assembly
CA3052204A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
JP7064501B2 (ja)	2017-02-17	2022-05-10	アムジエン・インコーポレーテツド	無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3050927A1 (en)	2017-03-06	2018-09-13	Brian Stonecipher	Drug delivery device with activation prevention feature
IL268478B2 (en)	2017-03-07	2023-10-01	Amgen Inc	Inserting a needle using super pressure
CA3052310A1 (en)	2017-03-09	2018-09-13	Amgen Inc.	Insertion mechanism for drug delivery device
EP3570871B1 (en)	2017-03-20	2020-11-18	H. Hoffnabb-La Roche Ag	Method for in vitro glycoengineering of an erythropoiesis stimulating protein
HUE063805T2 (hu)	2017-03-28	2024-01-28	Amgen Inc	Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
AU2018280054B2 (en)	2017-06-08	2023-07-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
MX2019014615A (es)	2017-06-08	2020-02-07	Amgen Inc	Dispositivo de administracion de farmacos accionado por par de torsion.
AU2018290281B2 (en)	2017-06-22	2021-12-16	Vertex Pharmaceuticals Incorporated	Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
EP3641857A1 (en)	2017-06-22	2020-04-29	Amgen Inc.	Device activation impact/shock reduction
AU2018290302B2 (en)	2017-06-23	2024-02-29	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (es)	2017-07-14	2024-06-11	Amgen Inc	Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
JP7649105B2 (ja)	2017-07-21	2025-03-19	アムジエン・インコーポレーテツド	薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr)	2017-07-25	2020-06-03	Amgen Inc	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en)	2017-08-18	2019-02-21	Amgen Inc.	BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
US11759565B2 (en)	2017-10-04	2023-09-19	Amgen Inc.	Flow adapter for drug delivery device
EP3691716B1 (en)	2017-10-06	2023-11-29	Amgen Inc.	Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en)	2017-10-09	2025-09-24	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
MA50528A (fr)	2017-11-03	2020-09-09	Amgen Inc	Systèmes et approches pour stériliser un dispositif d'administration de médicament
MA50553A (fr)	2017-11-06	2020-09-16	Amgen Inc	Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3707075A1 (en)	2017-11-06	2020-09-16	Amgen Inc.	Fill-finish assemblies and related methods
MX2020004736A (es)	2017-11-10	2020-08-13	Amgen Inc	Embolos para dispositivos de administracion de farmacos.
SG11202002772VA (en)	2017-11-16	2020-04-29	Amgen Inc	Autoinjector with stall and end point detection
WO2019099324A1 (en)	2017-11-16	2019-05-23	Amgen Inc.	Door latch mechanism for drug delivery device
JP7410860B2 (ja)	2017-12-29	2024-01-10	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法
PL3731873T3 (pl)	2017-12-29	2022-04-25	F. Hoffmann-La Roche Ag	Sposób dostarczania kompozycji pegylowanego białka
KR102523239B1 (ko)	2017-12-29	2023-04-18	에프. 호프만-라 로슈 아게	페길화 단백질 조성물을 제공하기 위한 방법
JP2021514656A (ja)	2018-03-02	2021-06-17	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
US20190351031A1 (en)	2018-05-16	2019-11-21	Halozyme, Inc.	Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CN112469454B (zh)	2018-07-24	2024-01-26	安进公司	用于施用药物的输送装置
MA53375A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
US12109389B2 (en)	2018-07-31	2024-10-08	Amgen Inc.	Fluid path assembly for a drug delivery device
DK3613486T3 (da) *	2018-08-24	2021-01-04	Uga Biopharma Gmbh	Metode og anlæg til rengøring af epo og/eller et epo-derivat
CA3106452A1 (en)	2018-09-24	2020-04-02	Amgen Inc.	Interventional dosing systems and methods
EP3856283A1 (en)	2018-09-28	2021-08-04	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en)	2018-10-02	2020-04-09	Amgen Inc.	Injection systems for drug delivery with internal force transmission
EP3860686A1 (en)	2018-10-05	2021-08-11	Amgen Inc.	Drug delivery device having dose indicator
AR116703A1 (es)	2018-10-15	2021-06-02	Amgen Inc	Proceso de ensamblaje de plataforma para un dispositivo de administración de fármacos
EA202191037A1 (ru)	2018-10-15	2021-08-05	Эмджен Инк.	Устройство доставки лекарственного средства, имеющее демпферный механизм
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
IL281908B2 (en)	2018-11-01	2025-06-01	Amgen Inc	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use
PH12021551405A1 (en)	2018-12-28	2022-05-11	Vertex Pharma	Modified urokinase-type plasminogen activator polypeptides and methods of use
MX2021012557A (es)	2019-04-24	2021-11-12	Amgen Inc	Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
CA3148261A1 (en)	2019-08-23	2021-03-04	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
WO2022063082A1 (zh)	2020-09-22	2022-03-31	美国杰科实验室有限公司	一种糖基化修饰的促红细胞生成素及其应用
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
AU2022271741A1 (en)	2021-05-10	2023-11-23	Chiome Bioscience Inc.	Purification method of antibody composition
EP4341161A1 (en)	2021-05-21	2024-03-27	Amgen Inc.	Method of optimizing a filling recipe for a drug container
WO2023209074A1 (en)	2022-04-28	2023-11-02	Institut National de la Santé et de la Recherche Médicale	Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
IL319976A (en)	2022-11-02	2025-05-01	Hoffmann La Roche	Method for producing glycoprotein compositions
CN116492448A (zh) *	2023-04-12	2023-07-28	深圳赛保尔生物药业有限公司	负载peg-epo及间充质干细胞的组合物、药物及其制备方法
WO2025227129A2 (en)	2024-04-25	2025-10-30	Starrock Pharma Llc	Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en)	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) *	1992-06-11	1997-10-07	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en)	1992-12-09	1995-07-26	Ortho Pharma Corp	Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
ZA946122B (en) *	1993-08-17	1995-03-20	Amgen Inc	Erythropoietin analogs
US5919455A (en) *	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0741187A2 (en)	1995-05-05	1996-11-06	F. Hoffmann-La Roche Ag	Recombinant obese (Ob) proteins
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) *	1996-05-15	2000-02-15	Hoffmann-La Roche Inc.	Pegylated obese (ob) protein compositions
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
DE69726571T2 (de) *	1997-09-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
JP2002531089A (ja)	1998-11-30	2002-09-24	イーライ・リリー・アンド・カンパニー	赤血球産生性化合物
PE20010288A1 (es) *	1999-07-02	2001-03-07	Hoffmann La Roche	Derivados de eritropoyetina
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001068141A2 (en)	2000-03-17	2001-09-20	Maxygen Aps	Dispersions of polypeptide conjugates
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1311285E (pt) *	2000-05-15	2005-06-30	Hoffmann La Roche	Composicao farmaceutica liquida contendo um derivado de eritropoietina

2000
- 2000-06-23 CZ CZ20002386A patent/CZ299516B6/cs not_active IP Right Cessation
- 2000-06-27 US US09/604,938 patent/US6583272B1/en not_active Expired - Lifetime
- 2000-06-27 SK SK987-2000A patent/SK286301B6/sk not_active IP Right Cessation
- 2000-06-28 DE DE122007000064C patent/DE122007000064I2/de active Active
- 2000-06-28 SI SI200030963T patent/SI1064951T1/sl unknown
- 2000-06-28 DE DE60036053T patent/DE60036053T2/de not_active Expired - Lifetime
- 2000-06-28 AT AT00113115T patent/ATE370748T1/de active
- 2000-06-28 EP EP07010693A patent/EP1839676A3/en not_active Withdrawn
- 2000-06-28 ID IDP20000533D patent/ID26447A/id unknown
- 2000-06-28 HR HR20000436A patent/HRP20000436B1/xx not_active IP Right Cessation
- 2000-06-28 DO DO2000000030A patent/DOP2000000030A/es unknown
- 2000-06-28 DK DK00113115T patent/DK1064951T3/da active
- 2000-06-28 IL IL13705600A patent/IL137056A0/xx active Protection Beyond IP Right Term
- 2000-06-28 PE PE2000000654A patent/PE20010297A1/es not_active IP Right Cessation
- 2000-06-28 CA CA002310536A patent/CA2310536C/en not_active Expired - Lifetime
- 2000-06-28 AU AU42744/00A patent/AU736067B2/en not_active Expired
- 2000-06-28 RS YUP-407/00A patent/RS49928B/sr unknown
- 2000-06-28 PT PT00113115T patent/PT1064951E/pt unknown
- 2000-06-28 TR TR2000/01956A patent/TR200001956A2/xx unknown
- 2000-06-28 ES ES00113115T patent/ES2289985T3/es not_active Expired - Lifetime
- 2000-06-28 NZ NZ505454A patent/NZ505454A/en not_active IP Right Cessation
- 2000-06-28 NO NO20003372A patent/NO327043B1/no not_active IP Right Cessation
- 2000-06-28 EP EP00113115A patent/EP1064951B1/en not_active Expired - Lifetime
- 2000-06-29 SG SG200003658A patent/SG92717A1/en unknown
- 2000-06-29 CN CNB001078895A patent/CN1184233C/zh not_active Expired - Lifetime
- 2000-06-29 AR ARP000103318A patent/AR024625A1/es active IP Right Grant
- 2000-06-29 CN CNB2004100036029A patent/CN1283664C/zh not_active Expired - Lifetime
- 2000-06-29 CO CO00048963A patent/CO5190661A1/es active IP Right Grant
- 2000-06-29 GT GT200000109A patent/GT200000109A/es unknown
- 2000-06-29 MY MYPI20002954A patent/MY128500A/en unknown
- 2000-06-29 GE GEAP20005430A patent/GEP20022804B/en unknown
- 2000-06-29 PA PA20008497801A patent/PA8497801A1/es unknown
- 2000-06-30 UY UY26228A patent/UY26228A1/es not_active IP Right Cessation
- 2000-06-30 KR KR1020000036976A patent/KR100593143B1/ko not_active Expired - Lifetime
- 2000-06-30 MX MXPA00006547A patent/MXPA00006547A/es active IP Right Grant
- 2000-06-30 IS IS5554A patent/IS2492B/is unknown
- 2000-06-30 DE DE10031839A patent/DE10031839A1/de not_active Ceased
- 2000-06-30 GB GB0016205A patent/GB2353281B/en not_active Expired - Lifetime
- 2000-06-30 BG BG104570A patent/BG65449B1/bg unknown
- 2000-06-30 ES ES200001625A patent/ES2191511B1/es not_active Expired - Fee Related
- 2000-06-30 OA OA1200000197A patent/OA11442A/fr unknown
- 2000-06-30 MA MA26014A patent/MA26746A1/fr unknown
- 2000-06-30 SV SV2000000120A patent/SV2002000120A/es active IP Right Grant
- 2000-06-30 IT IT2000MI001479A patent/IT1318606B1/it active
- 2000-06-30 GB GB0400086A patent/GB2393960C/en not_active Expired - Lifetime
- 2000-06-30 TW TW089112948A patent/TWI235667B/zh not_active IP Right Cessation
- 2000-06-30 HU HU0002553A patent/HU226233B1/hu active Protection Beyond IP Right Term
- 2000-06-30 TN TNTNSN00147A patent/TNSN00147A1/fr unknown
- 2000-07-02 GC GCP2000749 patent/GC0000197A/en active
- 2000-07-03 FR FR0008609A patent/FR2795734B1/fr not_active Expired - Lifetime
- 2000-07-03 BR BR0002276-4A patent/BR0002276A/pt not_active IP Right Cessation
- 2000-07-03 EA EA200000607A patent/EA003777B1/ru not_active IP Right Cessation
- 2000-07-03 JP JP2000201525A patent/JP3727009B2/ja not_active Expired - Lifetime
- 2000-07-03 BR BRPI0002276A patent/BRPI0002276B8/pt unknown
- 2000-07-03 PL PL341187A patent/PL202758B1/pl not_active IP Right Cessation
2002
- 2002-11-14 US US10/293,551 patent/US20030120045A1/en not_active Abandoned
2003
- 2003-12-17 JP JP2003419520A patent/JP2004155787A/ja active Pending
2006
- 2006-09-25 AR ARP060104175A patent/AR055650A2/es unknown
2007
- 2007-08-23 CY CY20071101097T patent/CY1107719T1/el unknown
- 2007-09-05 NL NL300289C patent/NL300289I9/nl unknown
- 2007-09-06 CY CY200700021C patent/CY2007021I1/el unknown
- 2007-09-12 LU LU91363C patent/LU91363I2/fr unknown
- 2007-10-19 FR FR07C0051C patent/FR07C0051I2/fr active Active
2009
- 2009-05-05 NO NO2009010C patent/NO2009010I2/no unknown

Also Published As

Publication number	Publication date
JP2004155787A (ja)	2004-06-03
MXPA00006547A (es)	2004-10-28
CO5190661A1 (es)	2002-08-29
CA2310536C (en)	2007-09-11
HRP20000436B1 (en)	2008-01-31
NO2009010I2 (no)	2014-06-02
LU91363I9 (no)	2018-12-31
KR100593143B1 (ko)	2006-06-26
CZ299516B6 (cs)	2008-08-20
EA200000607A1 (ru)	2001-02-26
AU736067B2 (en)	2001-07-26
EP1839676A2 (en)	2007-10-03
LU91363I2 (fr)	2007-11-12
KR20010049676A (ko)	2001-06-15
SK286301B6 (en)	2008-07-07
NL300289I1 (nl)	2007-11-01
ES2191511B1 (es)	2005-01-01
SK9872000A3 (en)	2002-06-04
AR055650A2 (es)	2007-08-29
TR200001956A2 (tr)	2001-01-22
PL202758B1 (pl)	2009-07-31
FR2795734B1 (fr)	2005-09-30
NL300289I9 (nl)	2019-08-21
JP2001064300A (ja)	2001-03-13
BRPI0002276B1 (pt)	2019-05-14
AU4274400A (en)	2001-01-04
AR024625A1 (es)	2002-10-16
EP1064951A2 (en)	2001-01-03
IL137056A0 (en)	2001-06-14
IS2492B (is)	2009-02-15
DE60036053D1 (de)	2007-10-04
NO2009010I1 (no)	2009-05-25
DE60036053T2 (de)	2008-01-03
SV2002000120A (es)	2002-01-31
HUP0002553A3 (en)	2005-11-28
ATE370748T1 (de)	2007-09-15
MA26746A1 (fr)	2004-12-20
GB2353281A (en)	2001-02-21
SI1064951T1 (sl)	2007-12-31
CY2007021I2 (el)	2009-11-04
NL300289I2 (nl)	2010-02-01
PT1064951E (pt)	2007-09-10
FR07C0051I2 (fr)	2008-05-09
CN1283664C (zh)	2006-11-08
CN1184233C (zh)	2005-01-12
GEP20022804B (en)	2002-09-25
HRP20000436A2 (en)	2001-06-30
US6583272B1 (en)	2003-06-24
NZ505454A (en)	2001-12-21
GB2393960B (en)	2004-08-04
HU226233B1 (en)	2008-07-28
ITMI20001479A1 (it)	2001-12-30
CZ20002386A3 (cs)	2002-04-17
NO327043B1 (no)	2009-04-06
CN1280137A (zh)	2001-01-17
TWI235667B (en)	2005-07-11
FR2795734A1 (fr)	2001-01-05
GB2393960C (en)	2012-08-29
GB0400086D0 (en)	2004-02-04
DE122007000064I2 (de)	2010-03-25
YU40700A (sh)	2003-12-31
EA003777B1 (ru)	2003-08-28
US20030120045A1 (en)	2003-06-26
HK1033328A1 (en)	2001-08-24
TNSN00147A1 (fr)	2005-11-10
BG104570A (en)	2001-09-28
EP1064951B1 (en)	2007-08-22
EP1064951A3 (en)	2002-03-20
CY1107719T1 (el)	2010-07-28
ES2289985T3 (es)	2008-02-16
HU0002553D0 (en)	2000-08-28
PE20010297A1 (es)	2001-03-07
DK1064951T3 (da)	2007-10-08
BRPI0002276B8 (pt)	2021-05-25
GC0000197A (en)	2006-03-29
DE122007000064I1 (de)	2008-01-03
ITMI20001479A0 (it)	2000-06-30
BR0002276A (pt)	2001-12-11
GB2353281B (en)	2004-06-09
CA2310536A1 (en)	2001-01-02
HK1068354A1 (en)	2005-04-29
OA11442A (fr)	2004-04-28
CY2007021I1 (el)	2009-11-04
FR07C0051I1 (no)	2007-12-14
PL341187A1 (en)	2001-01-15
RS49928B (sr)	2008-09-29
GB2393960A (en)	2004-04-14
IS5554A (is)	2001-01-02
UY26228A1 (es)	2000-10-31
NO20003372D0 (no)	2000-06-28
IT1318606B1 (it)	2003-08-27
JP3727009B2 (ja)	2005-12-14
HUP0002553A2 (en)	2001-03-28
GT200000109A (es)	2001-12-21
SG92717A1 (en)	2002-11-19
DOP2000000030A (es)	2002-07-15
ES2191511A1 (es)	2003-09-01
GB0016205D0 (en)	2000-08-23
DE10031839A1 (de)	2001-02-01
ID26447A (id)	2001-01-04
CN1515590A (zh)	2004-07-28
BG65449B1 (bg)	2008-08-29
EP1839676A3 (en)	2008-09-03
PA8497801A1 (es)	2001-12-14
MY128500A (en)	2007-02-28

Publication	Publication Date	Title
DK1064951T3 (da)	2007-10-08	Erythropoietinderivater
IS5381A (is)	2000-08-25	4-fenyl-pyridin afleiður
NO20021077D0 (no)	2002-03-05	Amino-triazolopyridin-derivater
ATE263748T1 (de)	2004-04-15	Admantan-derivate
ATE293104T1 (de)	2005-04-15	Thiazolylamid-derivate
IS6128A (is)	2001-10-26	13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da)	2004-12-20	5-phenyl-pyrimidinderivater
ATE338021T1 (de)	2006-09-15	Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803L (no)	2002-06-17	Isoksazolkarboksamid-derivater
ATE257148T1 (de)	2004-01-15	Propargyletherderivate
DK1154988T3 (da)	2004-11-22	Mevinolinderivater
ATE374747T1 (de)	2007-10-15	Monofluoralkylderivate
ATE254598T1 (de)	2003-12-15	4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de)	2005-05-15	Resorcinderivate
DK1187815T3 (da)	2006-06-19	4-phenyl-pyrimidinderivater
DK1189886T3 (da)	2006-05-15	Ethansulfonyl-piperidinderivater
NO20020212D0 (no)	2002-01-15	3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no)	2002-06-14	Syklopentenon-derivater
DE60001736D1 (de)	2003-04-24	1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE59909774D1 (de)	2004-07-22	1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date	Code	Title	Description
2014-06-02	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA (MIRCERA); NAT. REGISTRATION NO/DATE: EU107400001-16 20070903; FIRST REGISTRATION: GB EU107400001-16 20070720 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220720
2018-08-20	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA; REG. NO/DATE: EU107400001-16 20070903 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220724
2020-07-13	MK1K	Patent expired
2022-08-15	SPCX	Expiry of an spc	Spc suppl protection certif: 2009010